Skip to main content

Peer Review reports

From: Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma

Original Submission
30 Nov 2021 Submitted Original manuscript
5 Feb 2022 Author responded Author comments - Yasuyuki Mizutani
Resubmission - Version 2
5 Feb 2022 Submitted Manuscript version 2
8 Feb 2022 Editorially accepted
24 Feb 2022 Article published 10.1186/s12885-022-09272-2

You can find further information about peer review here.

Back to article page